Kevin Talbot, MD
Ophthalmology · Beaumont, TXNPI 1033522529
Payments from drug & device makers
Across 278 payments — averaging $1245.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$337K
- Beaver-visitec International, Inc.$3K
- Alcon$3K
- AbbVie$805
- Ocular Therapeutix, Inc.$763
- Johnson & Johnson Surgical Vision, Inc.$726
- plus $1K from 13 others
What the payments were for
- Consulting fees$10,35054%
- Speaking & faculty fees$320%
- Travel & lodging$1,4778%
- Food & beverage$7,14638%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 104 | $336,509 |
| Beaver-visitec International, Inc. | 4 | $3,380 |
| Alcon | 42 | $2,896 |
| AbbVie(2 entities) | 32 | $805 |
| Ocular Therapeutix, Inc. | 46 | $763 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $726 |
| Harrow Eye, LLC | 8 | $216 |
| Ivantis, Inc | 2 | $181 |
| Rxsight Inc | 5 | $179 |
| Bausch & Lomb Americas Inc. | 8 | $142 |
| Novartis | 6 | $117 |
| Dompe US, Inc. | 3 | $82 |
| Sun Pharmaceutical Industries Inc. | 2 | $62 |
| Tarsus Pharmaceuticals, Inc. | 2 | $46 |
| NEW World Medical,inc. | 1 | $40 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Thea Pharma Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Travoprost Intraocular Implant - iDose$8,115
- LenSx$1,386
- Clareon$1,268
- Wavelight Refractive Suite$1,134
- Voyager DSLT$1,033
- Unity$1,033
- iDoseTR$345
- CATALYS SYSTEM$150
- Tecnis IOL$150
- VERITAS Vision System$150
- Hydrus Microstent$149
- iStent Infinite$131
- Catalys Laser System$125
- DURYSTA$122
- ORA$115
- RXSIGHT CONTACT LENS$108
- RXSIGHT INJECTOR CARTRIDGE$108
- RXSIGHT INJECTOR HANDPIECE$108
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$108
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$108
How this compares
$346,218 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 69 | $79,202 |
| XiidraLifitegrast | 35 | $44,911 |
| CombiganBrimonidine Tartrate/Timolol | 72 | $29,072 |
| LumiganBimatoprost | 54 | $27,001 |
| Cyclosporine | 37 | $22,974 |
| RhopressaNetarsudil Mesylate | 39 | $16,367 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 59 | $13,784 |
| Latanoprost | 990 | $11,820 |
| Loteprednol Etabonate | 82 | $11,608 |
| Travoprost | 61 | $10,507 |
| Prednisolone Acetate | 300 | $9,544 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $8,962 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 547 | $8,877 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 27 | $8,427 |
| Fluorometholone | 79 | $5,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $805 | $140,748208 claims |
| Bausch & Lomb Americas Inc.Xiidra | $142 | $44,91135 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $16 | $25,33054 claims |
| AlconSimbrinza | $2,896 | $8,42727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Beaumont
- William PearceBeaumont$708K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.